Detailed company information
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 05, 2026
Earnings Transcript for 2026 - Q1Released: May 07, 2026
Earnings Transcript for 2025 - Q4Released: Feb 26, 2026
Earnings Transcript for 2025 - Q3Released: Oct 28, 2025
Earnings Transcript for 2025 - Q2Released: Aug 07, 2025
Earnings Transcript for 2025 - Q1Released: May 06, 2025
Earnings Transcript for 2024 - Q4Released: Feb 25, 2025
Earnings Transcript for 2024 - Q3Released: Nov 07, 2024
Earnings Transcript for 2024 - Q2Released: Aug 15, 2024
Earnings Transcript for 2024 - Q1Released: May 14, 2024
Earnings Transcript for 2023 - Q4Released: Feb 27, 2024
Earnings Transcript for 2023 - Q3Released: Nov 03, 2023
Earnings Transcript for 2023 - Q2Released: Aug 08, 2023
Earnings Transcript for 2023 - Q1Released: May 13, 2023
Earnings Transcript for 2022 - Q4Released: Feb 28, 2023
Earnings Transcript for 2022 - Q3Released: Nov 14, 2022
Arcutis Biotherapeutics plans a 20% expansion of its dermatology salesforce, expecting this strategic move to generate up to $25 million in additional revenue primarily in the second half of 2026. This growth in sales capacity supports the company's raised 2026 revenue guidance.
Read post
Dafinchi
